Incyte (INCY) Leases (2018 - 2026)
Incyte posted quarterly Leases of $26.7 million for Q1 2026, down 10.78% year-on-year from $29.9 million in Q1 2025, and down 3.09% on a QoQ basis from $27.5 million in Q4 2025.
Incyte (INCY) has 9 years of Leases data on file, last reported at $26.7 million in Q1 2026.
- For the quarter ending Q1 2026, Leases fell 10.78% year-over-year to $26.7 million; the trailing twelve-month figure through Mar 2026 stood at $26.7 million (down 10.78% YoY), and the FY2025 full-year result was $27.5 million, down 10.66% from the prior year.
- Leases for Q1 2026 stood at $26.7 million, down from $27.5 million in the prior quarter.
- Across five years, Leases topped out at $30.8 million in Q4 2024 and bottomed at $24.9 million in Q3 2023.
- The 5-year median for Leases is $26.7 million (2026), against an average of $26.9 million.
- The widest annual swing landed in 2024, when Leases gained 20.63%; it then slipped 10.78% in 2026.
- A 5-year view of Leases shows it stood at $26.3 million in 2022, then decreased by 2.9% to $25.5 million in 2023, then advanced by 20.63% to $30.8 million in 2024, then retreated by 10.66% to $27.5 million in 2025, then decreased by 3.09% to $26.7 million in 2026.
- The last three Leases figures came in at $26.7 million (Q1 2026), $27.5 million (Q4 2025), and $28.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 61,822.50 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 189.30 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 26.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.67 Mn |
| Dec 31, 2025 | 27.52 Mn |
| Sep 30, 2025 | 28.16 Mn |
| Jun 30, 2025 | 29.00 Mn |
| Mar 31, 2025 | 29.89 Mn |
| Dec 31, 2024 | 30.80 Mn |
| Sep 30, 2024 | 25.07 Mn |
| Jun 30, 2024 | 25.54 Mn |
| Mar 31, 2024 | 25.53 Mn |
| Dec 31, 2023 | 25.54 Mn |
| Sep 30, 2023 | 24.88 Mn |
| Jun 30, 2023 | 25.63 Mn |
| Mar 31, 2023 | 25.85 Mn |
| Dec 31, 2022 | 26.30 Mn |
| Sep 30, 2022 | 26.68 Mn |
| Jun 30, 2022 | 27.35 Mn |
| Mar 31, 2022 | 27.39 Mn |
| Dec 31, 2021 | 27.55 Mn |
| Sep 30, 2021 | 27.13 Mn |
| Jun 30, 2021 | 27.68 Mn |
| Mar 31, 2021 | 27.99 Mn |
| Dec 31, 2020 | 28.45 Mn |
| Sep 30, 2020 | 29.12 Mn |
| Jun 30, 2020 | 29.10 Mn |
| Mar 31, 2020 | 28.62 Mn |
| Dec 31, 2019 | 29.06 Mn |
| Sep 30, 2019 | 29.10 Mn |
| Jun 30, 2019 | 29.10 Mn |
| Dec 31, 2018 | 18.70 Mn |
| Sep 30, 2018 | 700,000.00 |